Atlas Trials

Leber Congenital Amaurosis

20 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Leber Congenital Amaurosis

RecordFirmDate
Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis (NCT05203939)Ocugen2022-01-24
An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene. (NCT04855045)ProQR Therapeutics2021-03-23
Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (NCT03920007)Atsena Therapeutics Inc.2019-10-22
Extension Study to Study PQ-110-001 (NCT03140969) (NCT03913130)Laboratoires Thea2019-05-13
A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE) (NCT03913143)ProQR Therapeutics2019-04-04
Clinical Trial of Gene Therapy for the Treatment of Leber Congenital Amaurosis (LCA) (NCT02781480)MeiraGTx UK II Ltd2016-04-01
Natural History Study of Patients With Leber Congenital Amaurosis Associated With Mutations in RPE65 (NCT02714816)MeiraGTx UK II Ltd2016-04-01
Inherited Retinal Degenerative Disease Registry (NCT02435940)Foundation Fighting Blindness2014-06-01
Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis (NCT00999609)Spark Therapeutics, Inc.2012-10-01
Clinical Gene Therapy Protocol for the Treatment of Retinal Dystrophy Caused by Defects in RPE65 (NCT01496040)Nantes University Hospital2011-09-01
Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2 (NCT01208389)Spark Therapeutics, Inc.2010-11-01
Genetic Decryption of Leber Congenital Amaurosis (LCA) in a Large Cohort of Independent Families. (NCT02970266)Assistance Publique - Hôpitaux de Paris2010-09-01
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford (NCT01793168)Sanford Health2010-07-01
Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis (NCT00749957)Beacon Therapeutics2009-06-17
Clinical Trial of Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations (NCT00821340)Hadassah Medical Organization2009-02-01
Safety Study in Subjects With Leber Congenital Amaurosis (NCT00516477)Spark Therapeutics, Inc.2007-09-01

Track Leber Congenital Amaurosis automatically

Every clearance here is in the API, with alerts when new ones post.